44 related articles for article (PubMed ID: 35567387)
1. Differential expression of TRKB tyrosine kinase in the two histological types of parotid salivary duct carcinoma with cancer aggressiveness.
Moriwaki K; Ayani Y; Kuwabara H; Terada T; Higashino M; Kawata R
Oral Oncol; 2024 Apr; 151():106751. PubMed ID: 38479153
[TBL] [Abstract][Full Text] [Related]
2. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.
Schmitt NC; Kang H; Sharma A
Oral Oncol; 2017 Nov; 74():40-48. PubMed ID: 29103750
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
McAfee JL; Hoda RS; Hoyle C; McCoy L; Sprague C; Reddy CA; Koyfman SA; Geiger JL; Komforti MK; Griffith CC
Mod Pathol; 2023 Oct; 36(10):100273. PubMed ID: 37423585
[TBL] [Abstract][Full Text] [Related]
4. Brain metastases in patients with salivary duct carcinoma: A retrospective study.
Fushimi C; Takahashi H; Kawakita D; Kano S; Tsukahara K; Ozawa H; Okami K; Sakai A; Yamazaki K; Okada T; Hanazawa T; Sato Y; Imanishi Y; Shimizu A; Matsuki T; Nagao T; Tada Y
Cancer Med; 2024 Mar; 13(5):e7037. PubMed ID: 38477487
[TBL] [Abstract][Full Text] [Related]
5. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center.
Mayer M; Wolber P; Prinz J; Jansen L; Esser J; Shabli S; Quaas A; Klußmann JP; Sharma SJ; Nachtsheim L; Arolt C
Eur Arch Otorhinolaryngol; 2024 Apr; ():. PubMed ID: 38587651
[TBL] [Abstract][Full Text] [Related]
6. Salivary Duct Carcinoma with Rhabdoid Features of the Parotid Gland with No E-Cadherin Expression: A Report with Anti-HER2 Therapy and Review of the Literature.
Jain R; Sansoni ER; Angel J; Gleysteen JP; Hayes DN; Owosho AA
Dent J (Basel); 2023 Sep; 11(10):. PubMed ID: 37886914
[TBL] [Abstract][Full Text] [Related]
7. Incurable advanced salivary gland tumours: a retrospective analysis and peek into the perplexing clinical and molecular intricacies from a tertiary care centre in India.
Sansar B; Singh N; Gupta A; Mishra BK; Sharma A; Rai R; Gupta P; Kapoor A
Ecancermedicalscience; 2023; 17():1602. PubMed ID: 37799960
[TBL] [Abstract][Full Text] [Related]
8. A 22-year single institution review of 119 cases of salivary duct carcinoma.
Han EJ; Mukdad LA; Alhiyari Y; Nakhla MN; Sajed DP; St John MA
Laryngoscope Investig Otolaryngol; 2024 Apr; 9(2):e1234. PubMed ID: 38525121
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of mammaglobin in salivary duct carcinomas de novo and salivary duct carcinoma ex pleomorphic adenoma.
Soares CD; de Lima Morais TM; Carlos R; Martins MD; de Almeida OP; Mariano FV; Altemani A
Hum Pathol; 2019 Oct; 92():59-66. PubMed ID: 31400353
[TBL] [Abstract][Full Text] [Related]
10. Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta-Analysis.
Key S; Chia C; Hasan Z; Sundaresan P; Riffat F; Dwivedi RC
Laryngoscope; 2024 Mar; 134(3):1042-1053. PubMed ID: 37610148
[TBL] [Abstract][Full Text] [Related]
11. Salivary duct carcinoma: A report of 70 FNA cases and review of the literature.
Wakely PE
Cancer Cytopathol; 2022 Aug; 130(8):595-608. PubMed ID: 35255198
[TBL] [Abstract][Full Text] [Related]
12. Role of HER2 in Prognosis of Salivary Duct Carcinoma: A Systematic Review and Meta-Analysis.
Williams CYK; Townson AT; Terry N; Schmitt NC; Sharma A
Laryngoscope; 2023 Mar; 133(3):476-484. PubMed ID: 35567387
[TBL] [Abstract][Full Text] [Related]
13. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
[TBL] [Abstract][Full Text] [Related]
14. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
